|
1.
|
Pound CR, Partin AW, Eisenberger MA, Chan
DW, Pearson JD and Walsh PC: Natural history of progression after
PSA elevation following radical prostatectomy. JAMA. 281:1591–1597.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Ward JF, Blute ML, Slezak J, Bergstralh EJ
and Zincke H: The long-term clinical impact of biochemical
recurrence of prostate cancer 5 or more years after radical
prostatectomy. J Urol. 170:1872–1876. 2003.PubMed/NCBI
|
|
3.
|
Bolla M, van Poppel H, Collette L, et al:
Postoperative radiotherapy after radical prostatectomy: a
randomised controlled trial (EORTC trial 22911). Lancet.
366:572–578. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Thompson IM, Tangen CM, Paradelo J, et al:
Adjuvant radiotherapy for pathological T3N0M0 prostate cancer
significantly reduces risk of metastases and improves survival:
long-term follow-up of a randomized clinical trial. J Urol.
181:956–962. 2009. View Article : Google Scholar
|
|
5.
|
Wiegel T, Lohm G, Bottke D, et al:
Achieving an undetectable PSA after radiotherapy for biochemical
progression after radical prostatectomy is an independent predictor
of biochemical outcome - results of a retrospective study. Int J
Radiat Oncol Biol Phys. 73:1009–1016. 2009. View Article : Google Scholar
|
|
6.
|
Buskirk SJ, Pisansky TM, Schild SE, et al:
Salvage radiotherapy for isolated prostate specific antigen
increase after radical prostatectomy: evaluation of prognostic
factors and creation of a prognostic scoring system. J Urol.
176:985–990. 2006. View Article : Google Scholar
|
|
7.
|
Stephenson AJ and Slawin KM: The value of
radiotherapy in treating recurrent prostate cancer after radical
prostatectomy. Nat Clin Pract Urol. 1:90–96. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Moreira DM, Banez LL, Presti JC Jr, et al:
Predictors of secondary treatment following biochemical recurrence
after radical prostatectomy: results from the Shared Equal Access
Regional Cancer Hospital database. BJU Int. 105:28–33. 2010.
View Article : Google Scholar
|
|
9.
|
Ost P, De Troyer B, Fonteyne V,
Oosterlinck W and De Meerleer G: A matched control analysis of
adjuvant and salvage high-dose postoperative intensity-modulated
radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys.
80:1316–1322. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Trabulsi EJ, Valicenti RK, Hanlon AL, et
al: A multi-institutional matched-control analysis of adjuvant and
salvage postoperative radiation therapy for pT3-4N0 prostate
cancer. Urology. 72:1298–1304. 2008. View Article : Google Scholar
|
|
11.
|
Cox JD, Stetz J and Pajak TF: Toxicity
criteria of the Radiation Therapy Oncology Group (RTOG) and the
European Organization for Research and Treatment of Cancer (EORTC).
Int J Radiat Oncol Biol Phys. 31:1341–1346. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Charlson ME, Pompei P, Ales KL and
MacKenzie CR: A new method of classifying prognostic comorbidity in
longitudinal studies: development and validation. J Chronic Dis.
40:373–383. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Extermann M: Measuring comorbidity in
older cancer patients. Eur J Cancer. 36:453–471. 2000. View Article : Google Scholar
|
|
14.
|
Aaronson NK, Ahmedzai S, Bergman B, et al:
The European Organization for Research and Treatment of Cancer
QLQ-C30: a quality-of-life instrument for use in international
clinical trials in oncology. J Natl Cancer Inst. 85:365–376. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
van Andel G, Bottomley A, Fossa SD, et al:
An international field study of the EORTC QLQ-PR25: a questionnaire
for assessing the health-related quality of life of patients with
prostate cancer. Eur J Cancer. 44:2418–2424. 2008.
|
|
16.
|
Stephenson AJ, Shariat SF, Zelefsky MJ, et
al: Salvage radiotherapy for recurrent prostate cancer after
radical prostatectomy. JAMA. 291:1325–1332. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Fayers P, Aaronson N, Bjordal K, Groenvold
M, Curran D and Bottomley A: EORTC QLQ-C30 scoring manual. European
Organization for Research and Treatment of Cancer; 3rd edition.
2001
|
|
18.
|
Michelson H, Bolund C, Nilsson B and
Brandberg Y: Health-related quality of life measured by the EORTC
QLQ-C30-reference values from a large sample of Swedish population.
Acta Oncol. 39:477–484. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Wahlgren T, Nilsson S, Lennernas B and
Brandberg Y: Promising long-term health-related quality of life
after high-dose-rate brachytherapy boost for localized prostate
cancer. Int J Radiat Oncol Biol Phys. 69:662–670. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Cox JD, Gallagher MJ, Hammond EH, Kaplan
RS and Schellhammer PF: Consensus statements on radiation therapy
of prostate cancer: guidelines for prostate re-biopsy after
radiation and for radiation therapy with rising prostate-specific
antigen levels after radical prostatectomy. American Society for
Therapeutic Radiology and Oncology Consensus. Panel J Clin Oncol.
17:11551999.
|
|
21.
|
Bernard JR Jr, Buskirk SJ, Heckman MG, et
al: Salvage radiotherapy for rising prostate-specific antigen
levels after radical prostatectomy for prostate cancer:
dose-response analysis. Int J Radiat Oncol Biol Phys. 76:735–740.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Kupelian PA, Willoughby TR, Reddy CA,
Klein EA and Mahadevan A: Hypofractionated intensity-modulated
radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate
cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys.
68:1424–1430. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
MacDonald OK, Schild SE, Vora S, et al:
Salvage radiotherapy for men with isolated rising PSA or locally
palpable recurrence after radical prostatectomy: do outcomes
differ? Urology. 64:760–764. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Choo R, Morton G, Danjoux C, Hong E,
Szumacher E and DeBoer G: Limited efficacy of salvage radiotherapy
for biopsy confirmed or clinically palpable local recurrence of
prostate carcinoma after surgery. Radiother Oncol. 74:163–167.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Neulander EZ and Soloway MS: Failure after
radical prostatectomy. Urology. 61:30–36. 2003. View Article : Google Scholar
|
|
26.
|
Tzou K, Tan WW and Buskirk S: Treatment of
men with rising prostate-specific antigen levels following radical
prostatectomy. Expert Rev Anticancer Ther. 11:125–136. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Boccon-Gibod L, Djavan WB, Hammerer P, et
al: Management of prostate-specific antigen relapse in prostate
cancer: a European Consensus. Int J Clin Pract. 58:382–390. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Cookson MS, Aus G, Burnett AL, et al:
Variation in the definition of biochemical recurrence in patients
treated for localized prostate cancer: the American Urological
Association Prostate Guidelines for Localized Prostate Cancer
Update Panel report and recommendations for a standard in the
reporting of surgical outcomes. J Urol. 177:540–545. 2007.
|
|
29.
|
Heidenreich A, Aus G, Bolla M, et al: EAU
guidelines on prostate cancer. Eur Urol. 53:68–80. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Amling CL, Bergstralh EJ, Blute ML, Slezak
JM and Zincke H: Defining prostate specific antigen progression
after radical prostatectomy: what is the most appropriate cut
point? J Urol. 165:1146–1151. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Godoy G, Tareen BU and Lepor H: Does
benign prostatic tissue contribute to measurable PSA levels after
radical prostatectomy? Urology. 74:167–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Stephenson AJ, Scardino PT, Kattan MW, et
al: Predicting the outcome of salvage radiation therapy for
recurrent prostate cancer after radical prostatectomy. J Clin
Oncol. 25:2035–2041. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Catton C, Gospodarowicz M, Warde P, et al:
Adjuvant and salvage radiation therapy after radical prostatectomy
for adenocarcinoma of the prostate. Radiother Oncol. 59:51–60.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Katz MS, Zelefsky MJ, Venkatraman ES, Fuks
Z, Hummer A and Leibel SA: Predictors of biochemical outcome with
salvage conformal radiotherapy after radical prostatectomy for
prostate cancer. J Clin Oncol. 21:483–489. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Maier J, Forman J, Tekyi-Mensah S, Bolton
S, Patel R and Pontes JE: Salvage radiation for a rising PSA
following radical prostatectomy. Urol Oncol. 22:50–56. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Pacholke HD, Wajsman Z, Algood CB, Morris
CG and Zlotecki RA: Postoperative adjuvant and salvage radiotherapy
for prostate cancer: impact on freedom from biochemical relapse and
survival. Urology. 64:982–986. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Valicenti RK, Gomella LG, Ismail M, et al:
Durable efficacy of early postoperative radiation therapy for
high-risk pT3N0 prostate cancer: the importance of radiation dose.
Urology. 52:1034–1040. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Anscher MS, Clough R and Dodge R:
Radiotherapy for a rising prostate-specific antigen after radical
prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys.
48:369–375. 2000.PubMed/NCBI
|
|
39.
|
Alongi F, Fiorino C, Cozzarini C, et al:
IMRT significantly reduces acute toxicity of whole-pelvis
irradiation in patients treated with post-operative adjuvant or
salvage radiotherapy after radical prostatectomy. Radiother Oncol.
93:207–212. 2009. View Article : Google Scholar
|
|
40.
|
Berglund A, Garmo H, Tishelman C, Holmberg
L, Stattin P and Lambe M: Comorbidity, treatment and mortality: a
population based cohort study of prostate cancer in PCBaSe Sweden.
J Urol. 185:833–840. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Widmark A, Klepp O, Solberg A, et al:
Endocrine treatment, with or without radiotherapy, in locally
advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase
III trial. Lancet. 373:301–308. 2009. View Article : Google Scholar
|
|
42.
|
Choo R, Danjoux C, Gardner S, et al:
Efficacy of salvage radiotherapy plus 2-year androgen suppression
for postradical prostatectomy patients with PSA relapse. Int J
Radiat Oncol Biol Phys. 75:983–989. 2009.
|
|
43.
|
Pai HH, Eldridge B, Bishop D, et al: Does
neoadjuvanthormone therapy improve outcome in prostate cancer
patients receiving radiotherapy after radical prostatectomy? Can J
Urol. 16:4541–4552. 2009.PubMed/NCBI
|
